| Hypoactive Sexual Desire Disorder
Addyi vs Vyleesi
Side-by-side clinical, coverage, and cost comparison for hypoactive sexual desire disorder.Deep comparison between: Addyi vs Vyleesi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyleesi has a higher rate of injection site reactions vs Addyi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyleesi but not Addyi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Addyi
Vyleesi
At A Glance
Oral
Daily
5-HT1A agonist/5-HT2A antagonist
SC injection
As needed
Melanocortin receptor agonist
Indications
- Hypoactive Sexual Desire Disorder
- Hypoactive Sexual Desire Disorder
Dosing
Hypoactive Sexual Desire Disorder 100 mg orally once daily at bedtime; discontinue after 8 weeks if no improvement in symptoms.
Hypoactive Sexual Desire Disorder 1.75 mg SC via autoinjector to the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity; no more than one dose within 24 hours; more than 8 doses per month not recommended; discontinue after 8 weeks if no improvement in symptoms.
Contraindications
- Concomitant use of moderate or strong CYP3A4 inhibitors
- Hepatic impairment
- Known hypersensitivity to flibanserin or any excipient, including anaphylaxis, angioedema, pruritus, or urticaria
- Uncontrolled hypertension
- Known cardiovascular disease
Adverse Reactions
Most common (>=2%) Dizziness, somnolence, nausea, fatigue, insomnia, dry mouth, anxiety, constipation
Serious Hypotension, syncope, CNS depression
Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, pruritus, urticaria), vomiting, asthenia, headache, presyncope, gait disturbance, vision blurred, brain fog
Most common (>=2%) nausea, flushing, injection site reactions, headache, vomiting, cough, fatigue, hot flush, paraesthesia, dizziness, nasal congestion
Serious transient increases in blood pressure and reductions in heart rate, focal hyperpigmentation, nausea, acute hepatitis
Pharmacology
The mechanism of action of flibanserin in HSDD is not known; in vitro, flibanserin acts as a 5-HT1A agonist and 5-HT2A antagonist, with moderate antagonist activity at 5-HT2B, 5-HT2C, and dopamine D4 receptors.
Bremelanotide is a melanocortin receptor (MCR) agonist that nonselectively activates several receptor subtypes (MC1R, MC4R, MC3R, MC5R, MC2R); at therapeutic doses, binding to MC1R and MC4R is most relevant, though the mechanism by which it improves HSDD in women is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Addyi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Vyleesi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Addyi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Vyleesi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Addyi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Vyleesi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Addyi.
$0/fillfill
Vyleesi Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VyleesiView full Vyleesi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.